Results 91 to 100 of about 11,291,129 (270)

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

Diagnosing Smoldering Multiple Myeloma and Light Chain Amyloidosis in the Setting of Severe Transthyretin Amyloid Cardiomyopathy and Extracardiac Sarcoidosis

Annals of Internal Medicine: Clinical Cases
Light chain (AL) amyloidosis involves deposition of monoclonal immunoglobulin light chain-derived amyloid fibrils, whereas ATTR amyloidosis involves deposition of insoluble antiparallel beta-pleated protein within tissues, leading to organ-specific ...
Robert A. Churchill, Andrew Rosenbaum
doaj   +1 more source

An unusual case of chronic lymphocytic leukemia, multiple myeloma and cardiac amyloidosis

Journal of Community Hospital Internal Medicine Perspectives, 2017
Light chain amyloidosis has very rarely been reported in association with chronic lymphocytic leukemia (CLL). We reported on a 76-years-old female who presented with simultaneous kappa-restricted chronic lymphocytic leukemia (CLL) and a lambda-restricted
Dongyan Liu, Hakim T. Uqdah, Alisha D. Gordy   +2 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Chronic Brucella infection associated with amyloid light chain cardiac amyloidosis: a case report

Frontiers in Cardiovascular Medicine
BackgroundAmyloidosis is a rare group of diseases characterized by extracellular deposition of amyloid fibrils. The most common types are amyloid light chain (AL) and transthyretin (ATTR), while serum amyloid A (AA) type is relatively rare.
RuiXia He, HaiJun Wang, LingMin Wu, Li Li, XinYuan Xu, GuoLi Ma, BaYaEr Qi, LiNa Ji, XiaoPing Liu   +8 more
doaj   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Therapeutic options in systemic AL amyloidosis

, 2004
Systemic amyloid light chain (AL) amyloidosis is a severe disease with unfavourable prognosis. Since the late 1970s different therapeutic modalities in AL amyloidosis have been investigated, trying to prolong survival.
Vellenga, E, Hazenberg, BPC; id_orcid, Lokhorst, H, van Gameren, [No Value]   +3 more
core   +1 more source

A Rare Case: Primary Pulmonary Amyloidosis

Düzce Tıp Fakültesi Dergisi
Amyloidosis is a rare disorder characterized by the extracellular deposition of insoluble protein aggregates. There are two common types of amyloidosis: Amyloid A (AA) and amyloid light chain (AL).
Ceyda Ceylan, Gülay Turan, Arslan Hirad Gani, Mustafa Kuzucuoğlu   +3 more
doaj   +1 more source